Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.
26 November 2024
26 November 2024
Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.